EAST LANSING, Mich. – Michigan State University scientists are testing a promising drug that may stop a gene associated with obesity from triggering breast and lung cancer, as well as prevent these cancers from growing.
These findings are based on two studies featured in the latest issue of Cancer Prevention Research.
The first was a preclinical study, led by Karen Liby, an associate professor in the Department of Pharmacology and Toxicology. Results showed that the drug, I-BET-762, is showing signs of significantly delaying the development of existing breast and lung cancers by zeroing in on how a cancerous gene, called c-Myc, acts.
“I-BET-762 works by targeting DNA so that this gene can’t be expressed,” Liby said. “It does this by inhibiting a number of important proteins – both in cancer and immune cells – ultimately reducing the amount of cancer cells in mice by 80 percent.”
These proteins are important because they play a critical role in what occurs between cells. For example, a particular protein, known as pSTAT3, can become activated in immune cells and stop them from doing their job, such as fighting off an invading cancer. The offending protein also can become overproduced in cancer cells
Article originally posted at